Biopharmaceutical company Xoma (XOMA) is having its luck day. After its stock traded down as low as $2.24, its shares are up almost 20% today on news that it bacterial cell expression technology to Pfizer to Pfzier (PFE). The deal comes with a $30 million up-front payment.
While that may not seem like much, XOMA lost $7.5 million on revenue of $14.1 million in the last quarter.
The stock still appears expensive, with a market cap of $370 million.
Maybe the royalties on the Pfizer deal, if there end up being any, will help justify the company’s valuation.
Douglas A. McIntyre
Smart Investors Are Quietly Loading Up on These “Dividend Legends”
If you want your portfolio to pay you cash like clockwork, it’s time to stop blindly following conventional wisdom like relying on Dividend Aristocrats.
There’s a better option, and we want to show you. We’re offering a brand-new report on 2 stocks we believe offer the rare combination of a high dividend yield and significant stock appreciation upside.
If you’re tired of feeling one step behind in this market, this free report is a must-read for you.
By providing your email address, you agree to receive communications from us regarding website updates and other offerings that may be of interest to you.
You have the option to opt-out of these emails at any moment. For more information, please review our Disclaimer and Terms of Use.
